Elisa Rizzo

Outcome of chemotherapy in advanced synovial sarcoma patients: Review of 15 clinical trials from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group; setting a new landmark for studies in this entity

Myrella Vlenterie, Saskia Litière, Elisa Rizzo et al. · European Journal of Cancer · 2016 · 151 citations

Medicine, Oncology, Surgery +14

Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents – Dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation for Research and Treatment of Cancer-led study

Sophie Postel‐Vinay, Laurence Collette, Xavier Paolettí et al. · European Journal of Cancer · 2014 · 122 citations

Medicine, Oncology, Pharmacology +17

Defining dose-limiting toxicity for phase 1 trials of molecularly targeted agents: Results of a DLT-TARGETT international survey

Xavier Paolettí, Christophe Le Tourneau, Jaap Verweij et al. · European Journal of Cancer · 2014 · 76 citations

Pharmacy, Pharmacology, Pharmacotherapy +16

Factors Predictive of Nonsentinel Lymph Node Involvement and Clinical Outcome in Melanoma Patients With Metastatic Sentinel Lymph Node

Carlo Riccardo Rossi, Gian Luca De Salvo, Elena Bonandini et al. · Annals of Surgical Oncology · 2007 · 66 citations

Medicine, Oncology, Pathology +17

Outcomes of First-Generation EGFR-TKIs Against Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Post Hoc Analysis of the BE-POSITIVE Study

Sara Pilotto, Antônio Rossi, Tiziana Vavalà et al. · Clinical Lung Cancer · 2017 · 46 citations

Medicine, Oncology, Molecular Oncology +9